An Overview on the Clinical Development of Tau-Based Therapeutics

An Overview on the Clinical Development of Tau-Based Therapeutics

Tauopathies such as Alzheimer’s disease (AD), frontotemporal lobar degeneration, or progressive supranuclear palsy constitute a group of brain disorders defined by neurodegeneration and the presence of tau aggregates in the affected brains regions. Tau is a microtubule-associated protein that accumu...

Full description

Bibliographic Details
Main Author:	Miguel Medina
Format:	Article
Language:	English
Published:	MDPI AG 2018-04-01
Series:	International Journal of Molecular Sciences
Subjects:	aggregation Alzheimer dementia drug development immunotherapy neurodegeneration tau tauopathies therapy
Online Access:	http://www.mdpi.com/1422-0067/19/4/1160

Similar Items

Editorial: Untangling the Role of Tau in Physiology and Pathology
by: Miguel Medina, et al.
Published: (2020-05-01)

Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease
by: Malcolm Roberts, et al.
Published: (2020-02-01)

New Features about Tau Function and Dysfunction
by: Miguel Medina, et al.
Published: (2016-04-01)

Modulation der Tau-Aggregation durch Modifikation der Cystein-Reste im Tau-Protein
by: Karras, Stephanie
Published: (2017)

Editorial: Tau Pathology in Neurological Disorders
by: Sonia Do Carmo, et al.
Published: (2021-09-01)

Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies
by: Benjamin Combs, et al.
Published: (2016-10-01)

Differences Between Human and Murine Tau at the N-terminal End
by: Félix Hernández, et al.
Published: (2020-01-01)

Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
by: Sebastian S. Oakley, et al.
Published: (2020-11-01)

TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia
by: Mauro Montalbano, et al.
Published: (2020-12-01)

Pathogenic Tau Causes a Toxic Depletion of Nuclear Calcium
by: Rebekah Mahoney, et al.
Published: (2020-07-01)

Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies
by: Pankajavalli Ramakrishnan, et al.
Published: (2003-11-01)

Untangling the Role of Tau in Physiology and Pathology
Published: (2020)

Targeting Tau to Treat Clinical Features of Huntington's Disease
by: Maria Masnata, et al.
Published: (2020-11-01)

A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies
by: Caterina Giacomini, et al.
Published: (2018-05-01)

Pharmacological Modulators of Tau Aggregation and Spreading
by: Antonio Dominguez-Meijide, et al.
Published: (2020-11-01)

Loss of tau rescues inflammation-mediated neurodegeneration
by: Nicole eMaphis, et al.
Published: (2015-06-01)

Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease
by: Garrett S. Gibbons, et al.
Published: (2020-11-01)

Targeting tauopathy with engineered tau-degrading intrabodies
by: Gilbert Gallardo, et al.
Published: (2019-10-01)

Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity
by: Luciana Medina, et al.
Published: (2021-03-01)

Tau Seeding Mouse Models with Patient Brain-Derived Aggregates
by: Aiko Robert, et al.
Published: (2021-06-01)

A walk through tau therapeutic strategies
by: Santosh Jadhav, et al.
Published: (2019-02-01)

The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?
by: Yann Fichou, et al.
Published: (2019-03-01)

Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice
by: Chun-ling Dai, et al.
Published: (2018-01-01)

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice
by: Nicholas B. Hastings, et al.
Published: (2017-05-01)

Tau exhibits unique seeding properties in globular glial tauopathy
by: Dah-eun Chloe Chung, et al.
Published: (2019-03-01)

The need for better AD animal models
by: Miguel eMedina, et al.
Published: (2014-10-01)

What is the evidence that tau pathology spreads through prion-like propagation?
by: Amrit Mudher, et al.
Published: (2017-12-01)

Intracellular and extracellular tau
by: Jesus Avila, et al.
Published: (2010-06-01)

The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD)
by: Barbara Mroczko, et al.
Published: (2019-09-01)

Untangling tau imaging
by: Victor L. Villemagne, et al.
Published: (2016-01-01)

Tau’s Three-Repeat Domain and EFhd2 Co-incubation Leads to Increased Thioflavin Signal
by: Irving E. Vega, et al.
Published: (2018-12-01)

Dural lymphatics regulate clearance of extracellular tau from the CNS
by: Tirth K. Patel, et al.
Published: (2019-02-01)

Role of the Lipid Membrane and Membrane Proteins in Tau Pathology
by: Eugene Bok, et al.
Published: (2021-04-01)

The Significance of Tau Aggregates in the Human Brain
by: Rudy J. Castellani
Published: (2020-12-01)

Tau-Cofactor Complexes as Building Blocks of Tau Fibrils
by: Yann Fichou, et al.
Published: (2019-12-01)

Characterization of tau binding by gosuranemab
by: Richelle Sopko, et al.
Published: (2020-12-01)

Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation
by: Aleksandra M. Wojtas, et al.
Published: (2020-12-01)

EFhd2 Affects Tau Liquid–Liquid Phase Separation
by: Irving E. Vega, et al.
Published: (2019-08-01)

Glial contributions to neurodegeneration in tauopathies
by: Cheryl E. G. Leyns, et al.
Published: (2017-06-01)

Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer
by: Stéphanie Papin, et al.
Published: (2020-11-01)

Cannot write session to /tmp/vufind_sessions/sess_i1dojcga7p39np4lsn0idq69b8